ProShare Advisors
XERS icon

ProShare Advisors’s Xeris Biopharma Holdings XERS Stock Holding History

ProShare Advisors’s Portfolio XERS Stock Details XERS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q3 		$266K Sell
27,853
-262
-0.9% -$2.21K ﹤0.01% 1421
2026
Q2 		$223K Sell
28,115
-2,365
-8% -$15.1K ﹤0.01% 1584
2026
Q1 		$177K Sell
30,480
-4,910
-14% -$32.6K ﹤0.01% 1620
2025
Q4 		$278K Buy
35,390
+3,383
+11% +$26.6K ﹤0.01% 1504
2025
Q3 		$261K Sell
32,007
-4,716
-13% -$31.3K ﹤0.01% 1527
2025
Q2 		$171K Sell
36,723
-358
-1% -$1.64K ﹤0.01% 1761
2025
Q1 		$204K Sell
37,081
-9,472
-20% -$38.2K ﹤0.01% 1674
2024
Q4 		$158K Sell
46,553
-24,051
-34% -$77.4K ﹤0.01% 1956
2024
Q3 		$201K Buy
70,604
+43,630
+162% +$112K ﹤0.01% 1728
2024
Q2 		$60.7K Sell
26,974
-6,614
-20% -$13.3K ﹤0.01% 1722
2024
Q1 		$74.2K Buy
33,588
+2,739
+9% +$7.09K ﹤0.01% 1862
2023
Q4 		$72.5K Buy
30,849
+4,537
+17% +$8.37K ﹤0.01% 1818
2023
Q3 		$48.9K Buy
26,312
+122
+0.5% +$279 ﹤0.01% 1717
2023
Q2 		$68.6K Buy
26,190
+1,179
+5% +$3K ﹤0.01% 1742
2023
Q1 		$40.8K Buy
+25,011
New +$31.3K ﹤0.01% 1686
2022
Q4 		– Sell
-26,029
Closed -$41K – 1894
2022
Q3 		$41K Buy
26,029
+601
+2% +$994 ﹤0.01% 1678
2022
Q2 		$39K Buy
25,428
+11,445
+82% +$24.2K ﹤0.01% 1731
2022
Q1 		$36K Sell
13,983
-3,578
-20% -$8.74K ﹤0.01% 2140
2021
Q4 		$51K Buy
17,561
+3,356
+24% +$7.25K ﹤0.01% 2283
2021
Q3 		$35K Buy
14,205
+2,280
+19% +$6.62K ﹤0.01% 1986
2021
Q2 		$49K Sell
11,925
-8,539
-42% -$32.6K ﹤0.01% 2359
2021
Q1 		$92K Buy
20,464
+2,723
+15% +$14.7K ﹤0.01% 2176
2020
Q4 		$87K Buy
17,741
+4,651
+36% +$23.3K ﹤0.01% 2006
2020
Q3 		$78K Buy
13,090
+2,010
+18% +$8.04K ﹤0.01% 1551
2020
Q2 		$29K Buy
+11,080
New +$38.6K ﹤0.01% 1647
2019
Q4 		– Sell
-10,344
Closed -$102K – 1804
2019
Q3 		$102K Buy
10,344
+314
+3% +$3.53K ﹤0.01% 1546
2019
Q2 		$115K Sell
10,030
-1,291
-11% -$13.6K ﹤0.01% 1517
2019
Q1 		$114K Buy
+11,321
New +$145K ﹤0.01% 1559

Other funds holding XERS

Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.92T AUM 36.1% 1-Year Est. Return
Nuveen
Nuveen Charlotte, North Carolina $420B AUM 34.97% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $551B AUM 33.95% 1-Year Est. Return
Vilga Financial Planning
Vilga Financial Planning Fair Lawn, New Jersey $168M AUM 23.03% 1-Year Est. Return
Essex Investment Management
Essex Investment Management Boston, Massachusetts $675M AUM 61.81% 1-Year Est. Return
Royce & Associates
Royce & Associates New York $11B AUM 39.4% 1-Year Est. Return
Citigroup
Citigroup New York $308B AUM 40.94% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $608B AUM 32.77% 1-Year Est. Return
Principal Financial Group
Principal Financial Group Des Moines, Iowa $195B AUM 21.17% 1-Year Est. Return
Squarepoint
Squarepoint New York $90.8B AUM 26.98% 1-Year Est. Return

ProShare Advisors's XERS Position: Q3 2026 in Review

ProShare Advisors reduced its Xeris Biopharma Holdings (XERS) stake by 0.93% in Q3 2026, selling an estimated $2.21K and leaving 27,853 shares worth $266K. The position accounts for ﹤0.01% of the portfolio, ranked #1421.

ProShare Advisors first reported a position in XERS in Q1 2019 and has held it in 28 quarters since. The position peaked at $278K in Q4 2025. 94 funds tracked by Wall St. Rank hold XERS as of Q3 2026.

  • ProShare Advisors held 27,853 shares of Xeris Biopharma Holdings worth $266K as of Q3 2026.
  • ProShare Advisors sold 262 Xeris Biopharma Holdings shares in Q3 2026, an estimated $2.21K.
  • Xeris Biopharma Holdings made up ﹤0.01% of ProShare Advisors's portfolio in Q3 2026, its #1421 holding.
  • ProShare Advisors first reported a position in Xeris Biopharma Holdings in Q1 2019 and has held it in 28 quarters since.
  • ProShare Advisors's Xeris Biopharma Holdings position peaked at $278K in Q4 2025.
  • 94 funds tracked by Wall St. Rank held Xeris Biopharma Holdings as of Q3 2026.

Based on ProShare Advisors's 13F filing for Q3 2026, filed 29 Oct 2026.